Sotera Health Company $SHC Shares Sold by Swiss National Bank

Swiss National Bank decreased its position in Sotera Health Company (NASDAQ:SHC) by 1.5% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 301,800 shares of the company’s stock after selling 4,600 shares during the period. Swiss National Bank owned about 0.11% of Sotera Health worth $3,519,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Deutsche Bank AG grew its holdings in Sotera Health by 1,902.2% in the first quarter. Deutsche Bank AG now owns 165,605 shares of the company’s stock valued at $1,931,000 after purchasing an additional 157,334 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Sotera Health by 5.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,415,282 shares of the company’s stock valued at $16,502,000 after purchasing an additional 68,087 shares during the last quarter. XTX Topco Ltd acquired a new stake in Sotera Health in the first quarter valued at $602,000. Victory Capital Management Inc. grew its holdings in Sotera Health by 5.7% in the first quarter. Victory Capital Management Inc. now owns 57,655 shares of the company’s stock valued at $672,000 after purchasing an additional 3,106 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Sotera Health by 0.3% in the first quarter. Principal Financial Group Inc. now owns 352,388 shares of the company’s stock valued at $4,109,000 after purchasing an additional 1,037 shares during the last quarter. Institutional investors and hedge funds own 91.03% of the company’s stock.

Wall Street Analyst Weigh In

SHC has been the topic of a number of analyst reports. Barclays reaffirmed an “overweight” rating on shares of Sotera Health in a research note on Friday, August 8th. Wall Street Zen raised Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Piper Sandler decreased their price objective on Sotera Health from $15.00 to $13.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 23rd. Finally, The Goldman Sachs Group raised Sotera Health from a “neutral” rating to a “buy” rating and increased their price objective for the company from $14.00 to $17.00 in a research note on Monday, May 5th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Sotera Health Stock Performance

NASDAQ SHC opened at $16.30 on Thursday. The business’s 50-day moving average price is $12.16 and its 200 day moving average price is $12.14. Sotera Health Company has a twelve month low of $9.53 and a twelve month high of $17.08. The company has a market capitalization of $4.63 billion, a PE ratio of 203.78 and a beta of 1.81. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 4.49.

Sotera Health (NASDAQ:SHC) last released its earnings results on Friday, August 8th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.03. Sotera Health had a return on equity of 39.42% and a net margin of 2.14%.The firm had revenue of $294.34 million for the quarter, compared to the consensus estimate of $275.81 million. During the same period in the prior year, the business posted $0.19 earnings per share. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. On average, research analysts predict that Sotera Health Company will post 0.61 earnings per share for the current year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.